Genetic Immunity, Inc. is a US / Hungarian biotechnology company. We are a wholly owned subsidiary of Power of the Dream Ventures, Inc. a technology holding company trading in the United States on the OTCBB under the symbol PWRV.
We maintain our research facilities in Hungary. Over the course of the last twelve years we have conducted three human clinical trails of our lead product candidate, a immunotherapy vaccine for the treatment of HIV. A Phase I trial in Hungary, an NIH financed and ACTG conducted Phase I/II trial in the United States, and a Phase II trial in Germany. All three trials have domstrated efficacay, immunogenicity, safaty and optimal dosege.
We are now working with our US regulatory expert, DJA GLobal Pharmaceuticals, Inc. on FDA submissions to receive clear guidance to achieve marketing approval.
If approved, our lead product candidate Dermavir will become the first new treatment option, a complement to antiretroviral therapy, in the fight against HIV.